Loading...
Loading...
PTPI| Name | Value |
|---|---|
| Revenues | 798.1K |
| Cost of Revenue | 881.3K |
| Gross Profit | -83.2K |
| Operating Expense | 4,017.9K |
| Operating I/L | -4,101.1K |
| Other Income/Expense | -130.7K |
| Interest Income | 0.0K |
| Pretax | -4,231.9K |
| Income Tax Expense | -10.5K |
| Net Income/Loss | -4,221.4K |
Petros Pharmaceuticals, Inc. specializes in men's health therapeutics, primarily focusing on the commercialization and development of Stendra, a prescription medication for erectile dysfunction (ED). Additionally, the company is involved in the development and commercialization of H100, a patented topical formulation for the treatment of acute Peyronie's disease. Petros Pharmaceuticals also markets a line of ED products in the form of vacuum erection device products, catering to the needs of individuals seeking solutions for men's health issues.
